Haozhou Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haozhou Tan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmadullah Ansari
IMAGINE Macromolecular Neutron Diffractometer, Biology and Soft Matter Division, Oak Ridge National Laboratory, USA
1 shared publication Alexandra Ford
Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA
1 shared publicationAshima Chopra
Center for Advanced Biotechnology and Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
1 shared publication- Bin Tan
Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, USA
1 shared publication - Eddy Arnold
Center for Advanced Biotechnology and Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
1 shared publication - Francesc Xavier Ruiz
Center for Advanced Biotechnology and Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
1 shared publication
Latest Publications
- Top Cited Papers
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6690) , 1434-1440
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral antivirals. The SARS-CoV-2 papain-like protease (PL pro ) is a promising but challenging drug target. We designed and synthesized 85 noncovalent PL pro inhibitors that bind to a recently discovered ubiquitin binding site and the known BL2 groove pocket near the S4 subsite. Leads inhibited PL pro with the inhibitory constant K i values from 13.2 to 88.2 nanomolar. The co-crystal structures of PL pro with eight leads revealed their interaction modes. The in vivo lead Jun12682 inhibited SARS-CoV-2 and its variants, including nirmatrelvir-resistant strains with EC 50 from 0.44 to 2.02 micromolar. Oral treatment with Jun12682 improved survival and reduced lung viral loads and lesions in a SARS-CoV-2 infection mouse model, suggesting that PL pro inhibitors are promising oral SARS-CoV-2 antiviral candidates.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 383 (6690) , 1434-1440
Top Cited PapersDesign of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral antivirals. The SARS-CoV-2 papain-like protease (PL pro ) is a promising but challenging drug target. We designed and synthesized 85 noncovalent PL pro inhibitors that bind to a recently discovered ubiquitin binding site and the known BL2 groove pocket near the S4 subsite. Leads inhibited PL pro with the inhibitory constant K i values from 13.2 to 88.2 nanomolar. The co-crystal structures of PL pro with eight leads revealed their interaction modes. The in vivo lead Jun12682 inhibited SARS-CoV-2 and its variants, including nirmatrelvir-resistant strains with EC 50 from 0.44 to 2.02 micromolar. Oral treatment with Jun12682 improved survival and reduced lung viral loads and lesions in a SARS-CoV-2 infection mouse model, suggesting that PL pro inhibitors are promising oral SARS-CoV-2 antiviral candidates.